SMS Finance

Market News

Hot Stocks: ANZ, South32, Perpetual, Downer EDI, Ventia, HMC Capital

ANZ appoints Nuno Matos as CEO On Monday, ANZ (ASX:ANZ) announced the appointment of Nuno Matos, former head of HSBC’s wealth and personal banking division, as its new CEO, effective July next year. Matos succeeds Shayne Elliott, who is stepping down after a nine-year tenure. Shares immediately fell in response. Over the past five days,

Hot Stocks: ANZ, South32, Perpetual, Downer EDI, Ventia, HMC Capital Read More »

Warner Bros Discovery splits streaming and cable businesses

Warner Bros Discovery (WBD) has announced a major restructuring that will divide its business into two distinct units: Global Linear Networks and Streaming & Studios. The reorganisation is expected to be completed by mid-2025. “Linear” refers to the traditional broadcasting model where viewers watch scheduled programming at specific times on a set channel. The Global

Warner Bros Discovery splits streaming and cable businesses Read More »

Downer subsidiary Spotless faces ACCC legal action

Infrastructure services company Downer EDI (ASX:DOW) has announced that Spotless Facility Services, a subsidiary, will defend civil proceedings initiated by the Australian Competition and Consumer Commission (ACCC). The ACCC’s allegations relate to conduct in 2019 and 2020 concerning estate maintenance services provided to the Department of Defence. The ACCC claims that Spotless, along with two

Downer subsidiary Spotless faces ACCC legal action Read More »

Surgical strike: Orthocell’s Remplir breaks into Singapore early

Orthocell (ASX:OCC) has achieved first sales of its peripheral nerve repair product Remplir in Singapore. This marks an early milestone ahead of a previously planned launch in the first quarter of 2025. Remplir is made from a collagen-based material that provides a protective environment for nerves during the healing process. It acts as a nerve

Surgical strike: Orthocell’s Remplir breaks into Singapore early Read More »

Immutep reports positive data in head and neck cancer trial

Immutep (ASX:IMM) has announced promising new data from its Phase IIb TACTI-003 trial, presented at the ESMO Immuno-Oncology Congress 2024. The trial combines the company’s lead drug candidate eftilagimod alpha (efti) with Merck & Co’s drug KEYTRUDA (pembrolizumab). The targeted indication is head and neck squamous cell carcinoma (HNSCC). Cancer cells hiding from T-cells T-cells

Immutep reports positive data in head and neck cancer trial Read More »

Scroll to Top